Hsin-Yao Tang

Hsin-Yao Tang

Auto-generated profile, based on publicly available information

Hsin-Yao Tang

Proteomics and Metabolomics Facility, Wistar Institute, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AKAmanpreet Kaur
Amanpreet Kaur
BEBrett L. Ecker
Brett L. Ecker
SDStephen M. Douglass
Stephen M. Douglass
CKCurtis H. Kugel
Curtis H. Kugel
MWMarie R. Webster
Marie R. Webster
AWAshani T. Weeraratna
Ashani T. Weeraratna
Physical changes in skin are among the most visible signs of aging. We found that young dermal fibroblasts secrete high levels of extracellular matrix (ECM) constituents, including proteoglycans, glycoproteins, and cartilage-linking proteins. The most abundantly secreted was HAPLN1, a hyaluronic and proteoglycan link protein. HAPLN1 was lost in aged fibroblasts, resulting in a more aligned ECM that promoted metastasis of melanoma cells. Reconstituting HAPLN1 inhibited metastasis in an aged microenvironment, in 3-D skin reconstruction models, and in vivo. Intriguingly, aged fibroblast-derived matrices had the opposite effect on the migration of T cells, inhibiting their motility. HAPLN1 treatment of aged fibroblasts restored motility of mononuclear immune cells, while impeding that of polymorphonuclear immune cells, which in turn affected regulatory T-cell recruitment. These data suggest that although age-related physical changes in the ECM can promote tumor cell motility, they may adversely affect the motility of some immune cells, resulting in an overall change in the immune microenvironment. Understanding the physical changes in aging skin may provide avenues for more effective therapy for older patients with melanoma. Significance: These data shed light on the mechanochemical interactions that occur between aged skin, tumor, and immune cell populations, which may affect tumor metastasis and immune cell infiltration, with implications for the efficacy of current therapies for melanoma. See related commentary by Marie and Merlino, p. 19. This article is highlighted in the In This Issue feature, p. 1

30 September 2022 in Science Immunology
Verified
Journal Article
Closed access
GMGauri Mirji
Gauri Mirji
AWAlison Worth
Alison Worth
SBSajad Ahmad Bhat
Sajad Ahmad Bhat
MSMohamed El Sayed
Mohamed El Sayed
TKToshitha Kannan
Toshitha Kannan
RSRahul S. Shinde
Rahul S. Shinde
The composition of the gut microbiome can control innate and adaptive immunity and has emerged as a key regulator of tumor growth, especially in the context of immune checkpoint blockade (ICB) therapy. However, the underlying mechanisms for how the microbiome affects tumor growth remain unclear. Pancreatic ductal adenocarcinoma (PDAC) tends to be refractory to therapy, including ICB. Using a nontargeted, liquid chromatography–tandem mass spectrometry–based metabolomic screen, we identified the gut microbe–derived metabolite trimethylamine N -oxide (TMAO), which enhanced antitumor immunity to PDAC. Delivery of TMAO intraperitoneally or via a dietary choline supplement to orthotopic PDAC-bearing mice reduced tumor growth, associated with an immunostimulatory tumor-associated macrophage (TAM) phenotype, and activated effector T cell response in the tumor microenvironment. Mechanistically, TMAO potentiated the type I interferon (IFN) pathway and conferred antitumor effects in a type I IFN–dependent manner. Delivering TMAO-primed macrophages intravenously produced similar antitumor effects. Combining TMAO with ICB (anti-PD1 and/or anti-Tim3) in a mouse model of PDAC significantly reduced tumor burden and improved survival beyond TMAO or ICB alone. Last, the levels of bacteria containing CutC (an enzyme that generates trimethylamine, the TMAO precursor) correlated with long-term survival in patients with PDAC and improved response to anti-PD1 in patients with melanoma. Together, our study identifies the gut microbial metabolite TMAO as a driver of antitumor immunity and lays the groundwork for potential therapeutic strategies targeting TMAO.

1 June 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MFMitchell E. Fane
Mitchell E. Fane
YCYash Chhabra
Yash Chhabra
GAGretchen M. Alicea
Gretchen M. Alicea
DMDevon A. Maranto
Devon A. Maranto
SDStephen M. Douglass
Stephen M. Douglass
AWAshani T. Weeraratna
Ashani T. Weeraratna

7 July 2016 in PLOS Biology
Verified
Journal Article
Open access
PDF file
JSJae Ho Seo
Jae Ho Seo
DRDayana B Rivadeneira
Dayana B Rivadeneira
MCM. Cecilia Caino
M. Cecilia Caino
YCYoung Chan Chae
Young Chan Chae
DSDavid W Speicher
David W Speicher
DADario C Altieri
Dario C Altieri
Mitochondria must buffer the risk of proteotoxic stress to preserve bioenergetics, but the role of these mechanisms in disease is poorly understood. Using a proteomics screen, we now show that the mitochondrial unfoldase-peptidase complex ClpXP associates with the oncoprotein survivin and the respiratory chain Complex II subunit succinate dehydrogenase B (SDHB) in mitochondria of tumor cells. Knockdown of ClpXP subunits ClpP or ClpX induces the accumulation of misfolded SDHB, impairing oxidative phosphorylation and ATP production while activating “stress” signals of 5′ adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and autophagy. Deregulated mitochondrial respiration induced by ClpXP targeting causes oxidative stress, which in turn reduces tumor cell proliferation, suppresses cell motility, and abolishes metastatic dissemination in vivo. ClpP is universally overexpressed in primary and metastatic human cancer, correlating with shortened patient survival. Therefore, tumors exploit ClpXP-directed proteostasis to maintain mitochondrial bioenergetics, buffer oxidative stress, and enable metastatic competence. This pathway may provide a “drugable” therapeutic target in cancer. As the powerhouse of the cell and a pivotal hub for oxidative stress, mitochondria must tightly control the state of the proteins that they contain, quickly eliminating misfolded, aggregated, or otherwise damaged proteins. Here, we show that tumor mitochondria manage their set of proteins by assembling an integrated network of protein homeostasis, or proteostasis, that controls both the folding and degradation of proteins. This protein complex is formed by the unfoldase-peptidase ClpXP, survivin, and the Hsp90-like chaperone TRAP-1, and regulates the function of the oxidative phosphorylation Complex II subunit succinate dehydrogenase B (SDHB). We find that interference with this process impairs energy production, promotes oxidative stress, and shuts down critical downstream signals important for tumor cell proliferation, invasion, and metastatic dissemination in vivo. Our results suggest that the mitochondrial proteostasis network may offer therapeutic opportunities in advanced disease.

4 June 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
GAGretchen M. Alicea
Gretchen M. Alicea
VRVito W. Rebecca
Vito W. Rebecca
AGAaron R. Goldman
Aaron R. Goldman
MFMitchell E. Fane
Mitchell E. Fane
SDStephen M. Douglass
Stephen M. Douglass
AWAshani T. Weeraratna
Ashani T. Weeraratna
Older patients with melanoma (>50 years old) have poorer prognoses and response rates to targeted therapy compared with young patients (<50 years old), which can be driven, in part, by the aged microenvironment. Here, we show that aged dermal fibroblasts increase the secretion of neutral lipids, especially ceramides. When melanoma cells are exposed to the aged fibroblast lipid secretome, or cocultured with aged fibroblasts, they increase the uptake of lipids via the fatty acid transporter FATP2, which is upregulated in melanoma cells in the aged microenvironment and known to play roles in lipid synthesis and accumulation. We show that blocking FATP2 in melanoma cells in an aged microenvironment inhibits their accumulation of lipids and disrupts their mitochondrial metabolism. Inhibiting FATP2 overcomes age-related resistance to BRAF/MEK inhibition in animal models, ablates tumor relapse, and significantly extends survival time in older animals. Significance: These data show that melanoma cells take up lipids from aged fibroblasts, via FATP2, and use them to resist targeted therapy. The response to targeted therapy is altered in aged individuals because of the influences of the aged microenvironment, and these data suggest FATP2 as a target to overcome resistance. See related commentary by Montal and White, p. 1255. This article is highlighted in the In This Issue feature, p. 1241

11 January 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SWShuai Wu
Shuai Wu
TFTakeshi Fukumoto
Takeshi Fukumoto
JLJianhuang Lin
Jianhuang Lin
TNTimothy Nacarelli
Timothy Nacarelli
YWYemin Wang
Yemin Wang
RZRugang Zhang
Rugang Zhang